Literature DB >> 25174958

Successful treatment of intraocular post-transplant lymphoproliferative disorder with intravenous rituximab.

Lawrence P Iu1, Jane C Yeung, Florence Loong, Alan K Chiang.   

Abstract

We reported a rare case of intraocular post-transplant lymphoproliferative disorder (PTLD) arising in a 3-year-old liver transplant recipient who had a prior history of systemic PTLD. The first PTLD entered remission after treatment with intravenous rituximab and withdrawal of immunosuppressants. One year after remission, she presented with granulomatous uveitis and iris nodules in the right eye. Iris biopsy confirmed recurrence of intraocular PTLD, which resolved completely after a second course of intravenous rituximab.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  anti-CD20 antibody; intraocular; post-transplant lymphoproliferative disorder (PTLD); rituximab

Mesh:

Substances:

Year:  2014        PMID: 25174958     DOI: 10.1002/pbc.25223

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

1.  Epstein-Barr virus induced post-transplant lymphoproliferative disorder presenting with unilateral retinal involvement.

Authors:  Mainguy Adam; Philippakis Elise; Aurélien Sutra Del Galy; Stanescu-Segall Dinu; Tadayoni Ramin; Bodaghi Bahram; Bonnin Sophie; Touhami Sara
Journal:  Am J Ophthalmol Case Rep       Date:  2021-08-02

2.  Ultra-low-dose (boom-boom) radiotherapy for management of recurrent ocular post-transplant lymphoproliferative disorder.

Authors:  Konstantin V Astafurov; Erick D Bothun; Nadia N Laack; Amanda J Deisher; Sanjay V Patel; Lauren A Dalvin
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.